Finally learning to read all PRs and Blog pieces a
Post# of 72440
(Total Views: 531)
Posted On: 05/01/2019 4:17:14 PM
Finally learning to read all PRs and Blog pieces and take awhile to digest them and re-read them before making any statements. First pass read thru didn't thrill me much, but reading others take and re-reading the PR today has led me to believe they may have found more to B-OM than originally thought due to the following statements today:
"Furthermore, our hope is that Brilacidin will eventually emerge as a treatment for other indications where SOM also is a frequent side-effect of cancer therapies.
It is time that the current standard of care for SOM takes a leap forward and a new market emerges," added Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. "I am reminded of drugs for not only rare diseases that were overlooked by the market during development and then went on to become 'company makers,' but also a drug such as Tagamet. Eventually, it became the first blockbuster drug ever by treating the common problem of acid reflux, a disease that was casually written off for decades as not having an effective treatment beyond antacids. Treatment-related SOM in cancer patients is a real problem worldwide, affecting millions of patients, with physical and financial ramifications that genuinely must be addressed beyond today's magic mouthwashes. And, we are currently the only company with an oral drug candidate being advanced into late-stage trials, positioned to fill this unmet need. I greatly look forward to initiating our planned Phase 3 program, adding further credibility and value to our Brilacidin Franchise."
His statements above lead me to believe B-OM could be used for far more uses than just head and neck chemo/rad patients, it becomes the treatment for a whole new market, it is mentioned alongside a 'company making' drug (and remember, this is just for SOM, just one of many, many indications for which Brilacidin is expected to provide disruptive treatment), and which should catapult Brilacidin into the "aware" space of most all in medicine.
Yes, what first seemed to be a bit of a 'fluffy' PR turned out IMO to be quite a tip off that the deal we are negotiating could be much bigger than thought at first blush and that is why Leo is milking it for the BEST deal.
"Furthermore, our hope is that Brilacidin will eventually emerge as a treatment for other indications where SOM also is a frequent side-effect of cancer therapies.
It is time that the current standard of care for SOM takes a leap forward and a new market emerges," added Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. "I am reminded of drugs for not only rare diseases that were overlooked by the market during development and then went on to become 'company makers,' but also a drug such as Tagamet. Eventually, it became the first blockbuster drug ever by treating the common problem of acid reflux, a disease that was casually written off for decades as not having an effective treatment beyond antacids. Treatment-related SOM in cancer patients is a real problem worldwide, affecting millions of patients, with physical and financial ramifications that genuinely must be addressed beyond today's magic mouthwashes. And, we are currently the only company with an oral drug candidate being advanced into late-stage trials, positioned to fill this unmet need. I greatly look forward to initiating our planned Phase 3 program, adding further credibility and value to our Brilacidin Franchise."
His statements above lead me to believe B-OM could be used for far more uses than just head and neck chemo/rad patients, it becomes the treatment for a whole new market, it is mentioned alongside a 'company making' drug (and remember, this is just for SOM, just one of many, many indications for which Brilacidin is expected to provide disruptive treatment), and which should catapult Brilacidin into the "aware" space of most all in medicine.
Yes, what first seemed to be a bit of a 'fluffy' PR turned out IMO to be quite a tip off that the deal we are negotiating could be much bigger than thought at first blush and that is why Leo is milking it for the BEST deal.
(9)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼